Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Elizabeth Fox, MD, MS

Elizabeth Fox, MD, MS

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Division of Oncology
CTRB4016
3501 Civic Center Blvd
Philadelphia, PA 19104
Education:
BS (Laboratory Sciences)
Northeastern University, College of Pharmacy & Allied Health, Boston, MA, 1988.
MD
Pennsylvania State University College of Medicine Hershey, PA, 1993.
MS (Clinical Research)
Duke University College of Medicine Durham, NC, 2006.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Geoerger B, Fox E, Pappo A, Yalon-Oren M, Marshall LV, Vézina C, Pathiraja K, Diede SJ, Ebbinghaus S, Park JR: Pembrolizumab in Pediatric Patients With Advanced Melanoma or a PD-L1–Positive Advanced, Relapsed, or Refractory Solid Tumor or Lymphoma: Phase 1/2 KEYNOTE-051 Study. International Society of Paediatric Oncology, Dublin Ireland October 2016.

Fox e and Balis FM: Letter to the Editor: 15-0600-Dr Fox’s response to letter to the editor: Tariquidar. Cancer Chemotherapy Pharmacology DOI 10.1007/s00280-016-3162-z. OCT 2016.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. : Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncology 34(12): 1368-75, Apr 2016.

Schafer E, Rau RE, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez GMV, Fox E, Weigel B, Blaney S : A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314). American Society of Clinical Oncology, Chicago, IL 2016.

Himebauch AS, SankarWN, Flynn JM, Sisko M, Moorthy G, Gerber JS, Zuppa AF, Fox E, Dormans JP, Kilbaugh TJ: Skeletal Muscle and Plasma Concentrations of Cefazolin during Complex Paediatric Spinal Surgery. Br J Anesthesia 2016.

Geoerger B, Fox E, Pappo AS, Oren MY, Marshall LV, Heath K, Diede SJ, Ebbinghaus S, Park JR: Phase 1/2 study of pembrolizumab in children with advanced melanoma or a PD-L1-positive (PD-L1+) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051). American Society of Clinical Oncology, Chicago, IL 2016.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen SG, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Tsao-Wei DD, Matthay KK, Mosse YP: Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium American Society of Clinical Oncology, Chicago, IL 2016.

32. DuBois SG , Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H , Goodarzian F, Shimada H, Boucher N, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP: Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Advance in Neuroblastoma Reesarch, Cairns, Australia 2016.

Balis FM, Womer RB, Berg SL, Adamson PC, Fox E: Current approach and recommendations for standardized dosing of anticancer drugs in infants. American Society of Clinical Oncology, Chicago, IL 2016.

Geller JI, Fox E, Turpin B, Reid JM, Liu X, Minard CG, Goldstein S, Weigel BJ: ADVL1315: A phase 1 study of the VEGF receptor tyrosine kinase inhibitor axitinib in children with recurrent or refractory solid tumors—A Children's Oncology Group study. American Society of Clinical Oncology, Chicago, IL 2016.

back to top
Last updated: 11/02/2016
The Trustees of the University of Pennsylvania